EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( RISE ‐ AMD ): Safety data

Mary Graciya Karunainathan iD, Celine Lee iD, Kaweh Daniel Zohalinejad iD, Mads Odgaard Mæng iD, Nanna Würtz Fabrin, Sigurrós Jónsdóttir, Anne Kjærsgaard Hassing, Søren Kveiborg Yde, Charles C Wykoff, Henrik Vorum iD, Yousif Subhi iD, Marie Ørskov iD und 1 weitere

Acta Ophthalmologica · 2026-12 · 104 (8)

DOI: 10.1111/aos.70160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Ophthalmologica, online erschienen am 27.05.2026. Verfasst von Mary Graciya Karunainathan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Wet Macular Degeneration, Intraocular Pressure. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD).

Methods

Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg. Safety data from May 2024 to October 2025 were obtained through a retrospective review of medical records by an experienced retina specialist and an additional reviewer. Symptomatic intraocular pressure (IOP) increase was defined as any symptom (e.g. pain) in conjunction with IOP > 21 mmHg.

Results

In total, 8675 intravitreal injections of aflibercept 8 mg were administered in 1429 eyes with nAMD, including 139 glaucomatous eyes. A total of 25 AEs were reported (2.88 per 1000 injections). Intraocular inflammation (IOI) was reported in 11 eyes (1.27 per 1000 injections), with 10 eyes being managed with topical dexamethasone, while one case required vitrectomy. Symptomatic IOP increase was observed in 10 cases (1.15 per 1000 injections). The occurrence of symptomatic IOP increase did not differ between glaucomatous and non‐glaucomatous eyes ( p = 0.24). Two cases of bacterial endophthalmitis were registered. No case of retinal vasculitis or retinal vascular occlusion was observed.

Conclusion

Incidence rates of symptomatic IOP increase and IOI were generally low. Despite a large glaucoma cohort, the higher incidence rate of symptomatic IOP increase in glaucomatous eyes did not reach statistical significance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsWet Macular DegenerationIntraocular PressureVisual AcuityDrug SubstitutionHumansRetrospective StudiesFemaleMaleIntravitreal InjectionsAngiogenesis InhibitorsAgedAged, 80 and overTreatment OutcomeDose-Response Relationship, DrugFollow-Up Studies

Stichwörter der Autor:innen

Eylea 8 mgadverse eventsaflibercept 8 mgage‐related macular degenerationintraocular inflammationintraocular pressure

Substanzen

afliberceptReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark.
  • Retina Consultants of Texas, Retina Consultants of America, Houston, Texas, USA.
  • Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

ORCID-Profile: Mary Graciya Karunainathan, Celine Lee, Kaweh Daniel Zohalinejad, Mads Odgaard Mæng, Henrik Vorum, Yousif Subhi, Marie Ørskov, Lasse Jørgensen Cehofski

Zitieren

APA

Karunainathan, M. G., Lee, C., Zohalinejad, K. D., Mæng, M. O., Fabrin, N. W., Jónsdóttir, S., Hassing, A. K., Yde, S. K., Wykoff, C. C., Vorum, H., Subhi, Y., Ørskov, M., & Cehofski, L. J. (2026). Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( RISE ‐ AMD ): Safety data. Acta Ophthalmologica, 104(8). https://doi.org/10.1111/aos.70160

Vancouver

Karunainathan MG, Lee C, Zohalinejad KD, Mæng MO, Fabrin NW, Jónsdóttir S, et al. Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( RISE ‐ AMD ): Safety data. Acta Ophthalmologica. 2026;104(8). doi:10.1111/aos.70160

BibTeX
@article{Karunainathan2026,
  author = {Karunainathan, Mary Graciya and Lee, Celine and Zohalinejad, Kaweh Daniel and Mæng, Mads Odgaard and Fabrin, Nanna Würtz and Jónsdóttir, Sigurrós and Hassing, Anne Kjærsgaard and Yde, Søren Kveiborg and Wykoff, Charles C and Vorum, Henrik and Subhi, Yousif and Ørskov, Marie and Cehofski, Lasse Jørgensen},
  title = {Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration ( RISE ‐ AMD ): Safety data},
  journal = {Acta Ophthalmologica},
  year = {2026},
  volume = {104},
  number = {8},
  doi = {10.1111/aos.70160}
}
Kostenlos starten →